logo-loader
viewRhinomed Ltd

Rhinomed Limited gets ready to raise

au_australian_dollar350_55f8a80268159.jpg

Technology firm Rhinomed Limited (ASX:RNO) has been granted a trading halt by the ASX, pending details of a capital raising.

The company has a very unique focus on nasal, respiratory and breathing management technologies, and is focussed on monetising applications for markets including sleep, wellbeing, drug delivery and sport.

Earlier in the month the company entered into a landmark partnership with SleepGP, a growing network of GP practices, to raise awareness of sleep disordered breathing issues within the family medicine setting.

Rhinomed's Mute™ is a unique nasal respiratory technology that has been found to reduce the volume and frequency of snoring in 75% of users.

The halt will remain in place until the opening of trade on Friday 18th September 2015, or earlier if an announcement is made to the market.

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Rhinomed Ltd

Price: 0.076 AUD

ASX:RNO
Market: ASX
Market Cap: $12.86 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tiziana Life Sciences: Dr Weiner announces 'completely novel' approach to...

Harvard Medical School's Dr Howard Weiner, who's also chairman of Tiziana Life Sciences' (LON:TILS)(NASDAQ:TLSA) scientific advisory board, speaks to Proactive London's Andrew Scott after winning a competitive research grant from the NIH (National Institutes of Health) to investigate the drug's...

4 hours, 39 minutes ago

2 min read